E2 ModerateModerate confidencePEM not requiredCross-SectionalPeer-reviewedMachine draft
Standard · 3 min
Comparison of serological and molecular test for diagnosis of infectious mononucleosis.
Salehi, Hassan, Salehi, Marziyeh, Roghanian, Rasoul et al. · Advanced biomedical research · 2016 · DOI
Quick Summary
This study compared two different tests for diagnosing infectious mononucleosis (IM), a viral infection caused by Epstein-Barr virus (EBV). Researchers tested 100 patients suspected of having IM and 100 healthy people using two methods: a blood test (ELISA) and a genetic test (PCR). The blood test was easier, faster, and cheaper than the genetic test, making it a better choice for initial diagnosis.
Why It Matters
Since EBV infection is considered a potential trigger or contributor to ME/CFS in some patients, accurate and accessible diagnostic methods are important. This study supports using ELISA as a practical screening tool, which could improve early identification of EBV-related illness and help researchers better understand the relationship between acute EBV infection and subsequent chronic fatigue development.
Observed Findings
PCR detected EBV DNA in 76% of suspected IM patients versus 20% of healthy controls.
ELISA showed EBV seropositivity in 68.5% of suspected IM patients versus 46% of healthy controls.
ELISA demonstrated applicability across various disease phases with higher sensitivity than PCR.
PCR is most useful 1-2 weeks after illness onset, limiting its practical diagnostic window.
Significant overlap in test positivity between case and control groups for both methods.
Inferred Conclusions
ELISA should be preferred as a first-line diagnostic test for infectious mononucleosis due to ease of use, cost-effectiveness, and shorter turnaround time.
PCR has limited clinical utility for IM diagnosis because of expense, time consumption, and delayed applicability after symptom onset.
Both serological and molecular methods show imperfect discrimination between infected patients and healthy controls.
ELISA can be applied across multiple phases of EBV infection with consistent performance.
Remaining Questions
What is the timeline of ELISA positivity relative to symptom onset, and how does this compare to PCR timing?
What This Study Does Not Prove
This study does not prove that EBV causes ME/CFS, nor does it establish whether acute EBV infection leads to chronic fatigue syndrome. It also does not demonstrate that ELISA is more accurate than PCR—only that it is more practical and cost-effective. The presence of EBV DNA or antibodies in healthy controls (20-46%) suggests EBV exposure is common and does not necessarily indicate active infectious mononucleosis.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →